Photo caption: Roche
Roche said on Thursday it agreed to acquire U.S. biotech firm 89bio (ETNB.O) for up to $3.5 billion to strengthen its development pipeline on liver and cardiometabolic disease treatments.
In a statement, the Swiss drugmaker said the deal was worth about $2.4 billion, or up to $3.5 billion when including a non-tradeable contingent value right.
=== Reuters ===
